176 related articles for article (PubMed ID: 12437504)
1. Developing strategies for liver fibrosis treatment.
Murphy F; Arthur M; Iredale J
Expert Opin Investig Drugs; 2002 Nov; 11(11):1575-85. PubMed ID: 12437504
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
[TBL] [Abstract][Full Text] [Related]
3. Pathobiology of liver fibrosis: a translational success story.
Lee YA; Wallace MC; Friedman SL
Gut; 2015 May; 64(5):830-41. PubMed ID: 25681399
[TBL] [Abstract][Full Text] [Related]
4. Cirrhosis--can we reverse hepatic fibrosis?
Tangkijvanich P; Yee HF
Eur J Surg Suppl; 2002; (587):100-12. PubMed ID: 16144208
[TBL] [Abstract][Full Text] [Related]
5. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
Nishikawa K; Osawa Y; Kimura K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308992
[TBL] [Abstract][Full Text] [Related]
6. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy.
Li D; Friedman SL
J Gastroenterol Hepatol; 1999 Jul; 14(7):618-33. PubMed ID: 10440206
[TBL] [Abstract][Full Text] [Related]
7. Hepatic fibrosis. Pathogenesis and principles of therapy.
Albanis E; Friedman SL
Clin Liver Dis; 2001 May; 5(2):315-34, v-vi. PubMed ID: 11385966
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies for liver fibrosis.
Fowell AJ; Iredale JP
Dig Dis; 2006; 24(1-2):174-83. PubMed ID: 16699275
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotic therapy in chronic liver disease.
Rockey DC
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):95-107. PubMed ID: 15704042
[TBL] [Abstract][Full Text] [Related]
10. Hepatic fibrosis--role of hepatic stellate cell activation.
Safadi R; Friedman SL
MedGenMed; 2002 Jul; 4(3):27. PubMed ID: 12466770
[TBL] [Abstract][Full Text] [Related]
11. Liver fibrosis: Common mechanisms and antifibrotic therapies.
Schuppan D
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S51-9. PubMed ID: 26189980
[TBL] [Abstract][Full Text] [Related]
12. CREB family: A significant role in liver fibrosis.
Li G; Jiang Q; Xu K
Biochimie; 2019 Aug; 163():94-100. PubMed ID: 31112743
[TBL] [Abstract][Full Text] [Related]
13. Targeted treatments for cirrhosis.
Fallowfield JA; Iredale JP
Expert Opin Ther Targets; 2004 Oct; 8(5):423-35. PubMed ID: 15469393
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Fibrosis: Emerging Therapies.
Friedman SL
Dig Dis; 2015; 33(4):504-7. PubMed ID: 26159266
[TBL] [Abstract][Full Text] [Related]
15. Hepatic stellate cells as a target for the treatment of liver fibrosis.
Bataller R; Brenner DA
Semin Liver Dis; 2001 Aug; 21(3):437-51. PubMed ID: 11586471
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model.
Karthikeyan S; Potter JJ; Geschwind JF; Sur S; Hamilton JP; Vogelstein B; Kinzler KW; Mezey E; Ganapathy-Kanniappan S
Biochem Biophys Res Commun; 2016 Jan; 469(3):463-9. PubMed ID: 26525850
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of liver fibrosis.
Hernandez-Gea V; Friedman SL
Annu Rev Pathol; 2011; 6():425-56. PubMed ID: 21073339
[TBL] [Abstract][Full Text] [Related]
18. Origin and function of myofibroblasts in the liver.
Wells RG; Schwabe RF
Semin Liver Dis; 2015 May; 35(2):97-106. PubMed ID: 25974896
[TBL] [Abstract][Full Text] [Related]
19. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.
Jaroszewicz J; Flisiak-Jackiewicz M; Lebensztejn D; Flisiak R
Expert Opin Investig Drugs; 2015; 24(9):1229-39. PubMed ID: 26122697
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents.
Böttcher K; Pinzani M
Adv Drug Deliv Rev; 2017 Nov; 121():3-8. PubMed ID: 28600202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
